ClinTec Appoints Austin Clark as Director Global Clinical Resourcing
News May 04, 2010
ClinTec International announces the extension of its senior management team with the appointment of Austin Clarke, Director of Global Clinical Resourcing. Austin brings over 9 years of experience in management and delivery of large scale resourcing programmes in healthcare and other industries. He gained a degree in Marketing from the University of Abertay in Dundee, UK before beginning his career within Recruitment Services in 2010.
Austin Clarke joins from global recruitment agency, Adecco, holding various sales and marketing positions in UK-based offices in Scotland, the South West of England and finally through promotion to country manager in Ireland. At ClinTec, Austin will further develop the Global Clinical Resourcing model on an international basis and manage ClinTec’s relationships with pharmaceutical companies at a senior level.
ClinTec International continues to invest in its Global Clinical Resourcing solution through ongoing Partnerships with major pharmaceutical companies. Following 13 years of successful business in Global Clinical Resourcing, in 2009, for one client alone (a major pharmaceutical company), ClinTec delivered 51 personnel (mainly CRAs) located across 17 different countries and sees further expansion in this area in the future.
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE